CNBX Pharmaceuticals Inc CNBX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $0.01
- Day Range
- $0.01–0.01
- 52-Week Range
- $0.01–0.05
- Bid/Ask
- $0.00 / $0.02
- Market Cap
- $336,002.60
- Volume/Avg
- 1.2 Mil / 194,843
Key Statistics
- Price/Earnings (Normalized)
- 0.03
- Price/Sales
- 0.45
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
CNBX Pharmaceuticals Inc is a biotechnology company. It develops pharmaceuticals focusing on cancer research utilizing HTS technology and personalized bioinformatics tools. The company's main focus is the development of cannabinoid therapies and other technologies for the treatment of cancer, mainly cancers of the gastrointestinal tract, skin, breast, and prostate. The firm's main product is the RCC-33, an oral capsule for the treatment of colorectal cancer. The company tools include delivery systems, personalized medicine diagnostics, and therapies based on Cannabinoid compounds.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 2
- Website
- https://www.cnbxpharma.com
Valuation
|
Metric
|
CNBX
|
|---|---|
Price/Earnings (Normalized) | 0.03 |
Price/Book Value | — |
Price/Sales | 0.45 |
Price/Cash Flow | — |
Price/Earnings
CNBX
Financial Strength
|
Metric
|
CNBX
|
|---|---|
Quick Ratio | 0.06 |
Current Ratio | 0.06 |
Interest Coverage | — |
Quick Ratio
CNBX
Profitability
|
Metric
|
CNBX
|
|---|---|
Return on Assets (Normalized) | −178.80% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
CNBX
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Zxzfcnnyv | Ygg | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Vkyzmgjx | Fsyfw | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Nlsjvbsml | Fxmfv | $97.8 Bil | |
MRNA
| Moderna Inc | Dlpmnjmz | Nywm | $41.3 Bil | |
ARGX
| argenx SE ADR | Jqygzlgfh | Xltm | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Hrzkzhgh | Yplwy | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Gwhsfmr | Fvpyft | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Vztmfmn | Zstsl | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Jqnhvqhqd | Pphsp | $12.5 Bil | |
INCY
| Incyte Corp | Fllqfwgs | Lrlnwg | $11.6 Bil |